FDA
-
-
-
-
-
-
-
Lexaria Releases Annual Letter from the CEO
-
-
-
-
-
-
-
Lexaria Bioscience raises $3.5 million in registered direct offering
-
-
-
-
-
-
-
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
-
-
-
-
-
-
-
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
-
-
-
-
-
-
-
Lexaria Bioscience (LEXX) Prices 2M Share Offering at $1/sh
-
-
-
-
-
-
-
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

